Do analysts recommend PLX or BLUW?

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 404.20%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PLX or BLUW?

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protalix BioTherapeutics $76.38M 2.51 $8.31M $0.18 13.22 Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A

Do analysts prefer JATT or BLUW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, JATT or BLUW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A

Is JATT or BLUW more profitable?

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Blue Water Acquisition Corp. III N/A N/A N/A

Do analysts rate BLUW or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, BLUW or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is BLUW or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A Invizyne Technologies N/A N/A N/A

Do analysts recommend BLUW or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, BLUW or ALVR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is BLUW or ALVR more profitable?

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A AlloVir N/A -71.03% -61.27%

Do analysts rate BLUW or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, BLUW or ZIVO?

Blue Water Acquisition Corp. III has higher earnings, but lower revenue than ZIVO Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A ZIVO Bioscience $15.85K 1,084.50 -$7.78M -$1.71 N/A

Is BLUW or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A ZIVO Bioscience N/A N/A -2,240.92%

Blue Water Acquisition Corp. III (BLUW) Competitors

$10.32 +0.01 (+0.05%)

Closing price 07/17/2026 03:50 PM Eastern

Extended Trading

$10.32 0.00 (-0.05%)

As of 07/17/2026 04:04 PM Eastern

Compare

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

Should you buy Blue Water Acquisition Corp. III stock or one of its competitors? MarketBeat compares Blue Water Acquisition Corp. III with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Blue Water Acquisition Corp. III include Protalix BioTherapeutics (PLX), JATT Acquisition (JATT), Invizyne Technologies (IZTC), AlloVir (ALVR), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector.

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 1.89 beat Protalix BioTherapeutics' score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Blue Water Acquisition Corp. III	Very Positive

Blue Water Acquisition Corp. III has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Blue Water Acquisition Corp. III's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.51	$8.31M	$0.18	13.22
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 404.20%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Protalix BioTherapeutics beats Blue Water Acquisition Corp. III on 6 of the 10 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

48.0% of JATT Acquisition shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Blue Water Acquisition Corp. III	N/A	N/A	N/A

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 1.89 beat JATT Acquisition's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Blue Water Acquisition Corp. III	Very Positive

Summary

JATT Acquisition and Blue Water Acquisition Corp. III tied by winning 3 of the 6 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Invizyne Technologies had 1 more articles in the media than Blue Water Acquisition Corp. III. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Blue Water Acquisition Corp. III. Blue Water Acquisition Corp. III's average media sentiment score of 1.89 beat Invizyne Technologies' score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Very Positive
Invizyne Technologies	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Blue Water Acquisition Corp. III beats Invizyne Technologies on 2 of the 3 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to AlloVir?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
AlloVir	N/A	-71.03%	-61.27%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 1.89 beat AlloVir's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Very Positive
AlloVir	Neutral

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Blue Water Acquisition Corp. III beats AlloVir on 4 of the 6 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 1.89 beat ZIVO Bioscience's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Very Positive
ZIVO Bioscience	Neutral

Blue Water Acquisition Corp. III has higher earnings, but lower revenue than ZIVO Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
ZIVO Bioscience	$15.85K	1,084.50	-$7.78M	-$1.71	N/A

12.8% of ZIVO Bioscience shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Blue Water Acquisition Corp. III and ZIVO Bioscience tied by winning 3 of the 6 factors compared between the two stocks.

Get Blue Water Acquisition Corp. III News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLUW vs. The Competition

Export

Metric	Blue Water Acquisition Corp. III	Biological Products, Except Diagnostic Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.20M	$350.82M	$6.89B	$12.43B
Dividend Yield	N/A	N/A	2.67%	8.84%
P/E Ratio	N/A	N/A	27.14	23.89
Price / Sales	N/A	191.30	524.02	90.49
Price / Cash	N/A	22.44	51.46	60.07
Price / Book	N/A	4.89	10.69	6.18
Net Income	N/A	-$141.03M	$3.59B	$331.73M
7 Day Performance	-0.07%	-1.83%	-2.18%	-2.09%
1 Month Performance	0.05%	1.03%	1.63%	-2.19%
1 Year Performance	7.22%	37.82%	25.56%	17.20%

Blue Water Acquisition Corp. III Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLUW Blue Water Acquisition Corp. III	N/A	$10.33 +0.0%	N/A	+7.2%	$290.20M	N/A	N/A	2	Positive News
PLX Protalix BioTherapeutics	2.2682 of 5 stars	$2.44 +3.0%	$12.00 +391.8%	+58.7%	$196.60M	$76.38M	N/A	200
JATT JATT Acquisition	N/A	$11.00 -5.2%	N/A	+761.2%	$92.29M	N/A	N/A	3
IZTC Invizyne Technologies	N/A	$6.97 -1.6%	N/A	-37.2%	$43.58M	N/A	N/A	29
ALVR AlloVir	N/A	$4.44 -1.1%	N/A	+87.4%	$22.39M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLUW) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Do insiders and institutionals have more ownership in PLX or BLUW?

Does the media favor PLX or BLUW?

Is PLX or BLUW more profitable?

Which has better earnings and valuation, PLX or BLUW?

Do analysts recommend PLX or BLUW?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Do institutionals & insiders hold more shares of JATT or BLUW?

Do analysts prefer JATT or BLUW?

Which has higher valuation & earnings, JATT or BLUW?

Is JATT or BLUW more profitable?

Does the media refer more to JATT or BLUW?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Is BLUW or IZTC more profitable?

Which has better earnings and valuation, BLUW or IZTC?

Does the media prefer BLUW or IZTC?

Do analysts rate BLUW or IZTC?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Is BLUW or ALVR more profitable?

Do analysts recommend BLUW or ALVR?

Which has better valuation & earnings, BLUW or ALVR?

Does the media refer more to BLUW or ALVR?

Do insiders & institutionals have more ownership in BLUW or ALVR?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Is BLUW or ZIVO more profitable?

Does the media refer more to BLUW or ZIVO?

Which has preferable valuation & earnings, BLUW or ZIVO?

Do insiders and institutionals have more ownership in BLUW or ZIVO?

Do analysts rate BLUW or ZIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools